Biocracked
Approach: conceptual metaphor. Palette: D, bold color field.

A single brass pocket-scale balance sits at the center of a saturated mustard-yellow seamless backdrop, shot straight-on from slightly below at eye level. Its two pans hang almost perfectly level. One pan holds a small pile of pale, matte white powder, and the other holds a similar pile, so the tiny, nearly equal difference reads at a glance. A thin electric green thread is tied around the balance's pointer, a subtle accent. Soft, large-window studio light comes from the left and casts a crisp, short shadow to the right on the glossy surface below. Shallow depth of field blurs the background edges. The mood is quiet, skeptical and unresolved, with a clean, editorial look. No text, numerals or markings are visible on the scale.
Longevity

Rapamygen Gagal Ing Tes Umur Panjang Manungsa Sing Gedhé. Iki Sing Nggawé Kaget

Dr. Synapse · · 3 min read

Yen sampeyan ngikuti gegeran rapamygen kanggo umur panjang, kabar iki bakal nglarani: panliten paling gedhé sing ndelok paparan rapamygen jangka panjang ing manungsa ora nemokake manfaat umur sing berarti. Nanging sadurunge sampeyan mbuwang pil, waca cathetan cilik iki.

Angka‑angka Utama

Ing artikel sing dipun terbitaké ing Geroscience, Darren Stewart (NYU Langone Health) lan William Fitzsimmons (University of Illinois at Chicago) nyinaoni data registri transplantasi organ nasional AS. Padha mbandhingaké:

  • 4.885 pasien transplantasi ginjal sing diparingi rapamygen (inhibitor mTOR)
  • 6.589 pasien transplantasi sing ora diparingi rapamygen

Pasien dipantau kanthi median 11 taun, lan 6.443 wong séda sajrone periode panliten. Kabèh pasien wis ngliwati taun kapisan sawisé transplantasi kanthi graft sing isih mlaku.

Sawisé diwènèhi bobot nggunakake propensity score, umur rata‑rata urip median yaiku 64,6 taun ing grup rapamygen lan 64,3 taun ing grup non‑rapamygen. Interval kapercayan 95 % kanggo bedané yaiku saka ‑1,6 nganti +2,0 taun. Para penulis nyatakaké yèn “ora ditemokaké peningkatan urip jangka panjang sing berarti amarga inhibisi mTOR.”

Sumber: PubMed 42989006 | DOI 10.1007/s11357-026-02643-8

Napa Panliten Iki Penting

Rapamygen dadi salah siji calon anti‑penuaan sing paling akèh dibahas, nanging penulis nyatakake yèn panliten manungsa sing ana isih sithik. Akèh antusiasme asalé saka asil ing kéwan lan pangerten mekanistik. Dataset iki kalebu salah siji sing paling gedhé sing ndelok paparan kronis rapamygen ing wong, kanthi ewu pati kanggo dianalisis, dudu biomarker jangka pendek.

Para peneliti uga nyetel variabel kaya umur, BMI, diabetes lan 15 faktor liya. Iku penting merga wong sing diparingi obat asring béda sacara sistematis karo wong sing ora diparingi.

Cathetan Penting (Wacanen Sadurunge Nglakokake Kesimpulan)

1. Populasi iki pasien transplantasi. Kabeh sing melu panliten iku wis nampa transplantasi ginjal lan kudu nampa imunosupresi saklawasé urip. Kesehatan dhasar, risiko, lan penyebab mati padha béda karo wong sing sehat lan kepengin umur panjang. Obat bisa waé migunani kanggo nglawan penuaan ing wong sehat, nanging ora katon ing setting iki.

2. Konteks dosis imunosupresif. Ing kedokteran transplantasi, rapamygen digunakaké kanggo nindhes sistem imun lan njaga graft. Iki beda banget karo dosis cilik, asring minggon, sing dibahas déning pangguna longevity. Abstrak artikel ora nyoba utawa ndhukung protokol longevity apa wae, mula aja diwaca minangka putusan final babagan dosis intermiten. Ing sisih liya, artikel iki uga ora menehi bukti yèn dosis intermiten efektif.

3. Panliten iki observasional. Propensity weighting nyuda ketimpangan sing diukur, nanging ora bisa mbusak confounding sing ora diukur. Pasien bisa diparingi rapamygen amarga alasan klinis tartamtu, sing bisa ngebias asil ing salah siji arah. Desain iki mung nuduhaké asosiasi, ora bukti sebab‑akibat.

4. Interval kapercayan ora sempit. Rentang ‑1,6 nganti +2,0 taun ngecualikaké manfaat utawa bahaya gedhé, nanging ora ngecualikaké efek moderat. “Ora ana peningkatan sing berarti” ora padha karo “bukti ora ana efek.”

5. Seleksi survivor. Mung pasien sing urip lan grafté isih fungsi sawise setaun pisanan sing kalebu, mula panliten iki ora ngomong apa-apa babagan asil ing taun‑taun awal.

Apa Tegese Kanggo Panganggo Dosis Intermiten Longevity

Mangkene wacan jujur:

  • Optimisme entuk pukulan. Yèn rapamygen nduwèni efek umur sing kuat lan umum ing manungsa, sinyal bisa wae katon ing kohort gedhé kaya iki. Nanging ora ana.
  • Pitakonan durung rampung. Bukti paling kuat babagan umur dawa rapamygen isih asalé saka studi kéwan (konteks latar, ora saka artikel iki). Apa dosis cilik, intermiten ing wong sehat bisa ngowahi umur utawa healthspan isih durung dites ing dataset iki.
  • Aja nyimpulaké ing loro arah. Panliten iki ora negesaké utawa mbantah regimen longevity off‑label.

Praktis Takeaways

  • Dosis lan wektu: Artikel iki ora nyebutake dosis umur panjang, lan durung ana dosis sing wis dibuktekaké ing manungsa. Sapa waé sing kepéngin nyoba rapamygen kudu kerja bareng dokter sing bisa ngawasi. Aja njupuk dosis transplantasi utawa protokol online kanthi blaka.
  • Sing isih bisa kepengin: Wong diwasa sing penasaran babagan geroscience, luwih becik melu uji klinis utawa ing pangawasan medis, karo pangarepan realistis yèn manfaat umur durung kabukten.
  • Sing kudu ngindari utawa ati‑ati banget: Penerima transplantasi kudu ora ngowahi rejimen imunosupresi dewe. Sapa waé sing duwe infèksi aktif, penyembuhan luka sing alon, utawa njupuk obat sing sesambungan kudu takon dhokter dhisik, amarga rapamygen mengaruhi sistem imun lan metabolisme.
  • Mindset trade‑off: Rapamygen iku obat sing modhifikasi imun, lan panliten iki nuduhaké yèn ora ana bayaran urip sing katon kanggo ngimbangaké risiko kasebut.

Ringkesan

Iki cekelan realitas sing tenang, dudu putusan final. Ing 11.474 pasien transplantasi ginjal sing dipantau kanthi median 11 taun, pangguna rapamygen lan non‑pangguna nduwèni umur median sing padha (64,6 vs 64,3 taun). Populasi, dosis, lan desain observasional matesi sejauh apa asil iki bisa digeneralisasi. Kanggo pangguna longevity, pelajarané yaiku tetep wicaksana karo hype lan ngentèni uji klinis randomisasi ing wong sehat.

Para penulis nglaporake hubungan konsultasi karo perusahaan sing ora ana hubungane karo panliten iki lan nyatakaké ora ana konflik kepentingan.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Conceptual metaphor: a sheet of thick, clear laboratory glass standing upright, with a single hairline fracture running diagonally across it. A thin ribbon of vivid electric-green liquid seeps through the crack and drips onto a glossy white surface below. The glass is photographed straight on, at a slight low angle, in crisp macro focus along the fracture edges, where tiny chips catch the light. The backdrop is a seamless, saturated tomato-red field that fills the frame. Soft, directional studio light from the left creates bright refraction lines along the glass edge and a clean, warm-red tinted shadow on the right. The mood is tense but revealing, a long-held assumption starting to give way. Empty space on the right balances the composition. No text, no people, and no blue cast.
longevity

Rapamycin 'Ora Bisa Nglangkungi Otak'? Napa Mitos Iki Kiwari Runtuh

BY DR. SYNAPSE ·

"Rapamycin ora bisa nglangkungi otak" iku klaim sing asring muncul ing kalangan longevity, lan ulasan anyar nerangake manawa klaim iki adhedhasar pangukuran sing keliru. Sanajan rapamycin arang ditemokake ing cairan serebrospinal, bukti saka jaringan glioblastoma, kontrol kejang ing tuberous sclerosis, PET ing Alzheimer, lan aliran darah ing pembawa APOE4 kabeh nuduhaké aktivitas nyata ing otak. Nanging, nganti saiki durung ana sing ngukur rapamycin langsung ing otak sehat manungsa nganggo dosis terapeutik. Ing ngisor iki apa sing didhukung bukti, apa sing ora, lan sapa sing kudu mikir kaping pindho.

Approach: conceptual metaphor, in palette D (bold color field).

A saturated mustard-yellow backdrop holds seven identical wooden-handled stopwatches in a staggered row, shot from a slightly raised three-quarter angle. Five stopwatches have run on and show tarnished, cloudy glass faces. The two in front have clean, glossy glass, and each carries a small electric green (#00e676) ribbon tied to its crown. The faces carry no numerals or readable marks. Soft, even studio light from a large overhead softbox gives gentle, short shadows. Shallow depth of field blurs the back of the row. The mood is playful but analytical, with crisp contrast between the dull watches and the bright pair. The image suggests that extra time and good time are not the same thing.
longevity

Sulforaphane lan Metformin Menang Nalika Lima Senyawa Umur Panjang Gagal

BY DR. SYNAPSE ·

Pitu senyawa umur panjang sing kondhang kabeh bisa nambah umur cacing *C. elegans* jantan ing studi *GeroScience* anyar, nanging mung loro sing njaga fungsi kewan nalika wis tuwa. Sulforaphane lan metformin siji-sijine perlakuan sing ningkatake kasil kawin ing umur akhir, minangka indikator kesehatan reproduksi. Lima senyawa liyane mung nambah dina urip tanpa njaga fungsi kasebut, nuduhake yèn umur lan kesehatan bisa dipisahaké. Riset iki mung ing cacing, ora dadi bukti kanggo manungsa. Nanging, temuan iki nyaranake supaya skrining senyawa umur panjang fokus marang fungsi, ora mung umur panjang.

Approach: macro science. Palette: bold color field (violet).

Extreme close-up of fisetin crystals, a small cluster of pale yellow needle-like flavonoid crystals with translucent, faceted edges, resting on a smooth glossy deep violet surface. The camera sits low at a shallow three-quarter angle with a very shallow depth of field, so the front crystals are razor sharp and the rest dissolves into soft magenta-violet blur. Lighting is a single crisp, slightly warm studio key from upper left that makes the crystal edges glow and throws long soft shadows across the violet. A few tiny electric green (#00e676) specks of reflected light catch on the crystal tips. The mood is precise, curious and quietly promising, like a sample under inspection, with plenty of clear violet space on the right side of the frame.
longevity

Fisetin Senolitik Nambah Umur Tikus—Bukti Kanggo Manungsa Isih Durung Ana

BY HELIX WARD ·

Fisetin, flavonoid saka tanduran, dadi senolitik paling kuat saka sepuluh senyawa ing studi EBioMedicine 2018 sing asring dirujuk. Ing tikus tuwa sing diwenehi perawatan ing pungkasan urip, tandha‑tandha senesensi mudhun, patologi terkait umur berkurang, lan umur median lan maksimum dadi luwih dawa. Nanging bukti iki mung saka percobaan tikus lan sel, dudu percobaan umur manungsa sing rampung. Artikel iki nerangake temuan peneliti, dosis sing digunakake, lan sapa sing kudu nggatekake nalika studi manusia wiwit muncul.

Approach: conceptual metaphor. Palette: bold color field.

A single steel bathroom-style analog tape measure, pulled taut and wrapped around a ripe, glossy yellow-orange pear lying on its side, with the tape's tip locked at the same unmarked point, suggesting a waistline that did not shrink. The pear sits on a saturated magenta seamless backdrop, shot from a low three-quarter angle with a shallow depth of field, the stem sharp and the background softly blurred. Hard but slightly diffused studio key light from upper left casts a crisp, short shadow in deeper magenta on the surface. A tiny electric green sticky dot marks the tape's end, with no numbers or writing visible. Mood: playful, skeptical, deadpan, scientific restraint rather than hype.
longevity

Rapamycin Mingguan Sajerone Taun: Aman, Nanging Apa Lemak Visceral Nggowahi?

BY REX MERIDIAN ·

Saben wong kepengin ngerti apa rapamycin mingguan bisa nyuda lemak visceral lan ningkatake healthspan. Uji coba PEARL maringi jawaban sing bisa ngagetaké. Sawisé 48 minggu ing wong diwasa sing sehat, asil utama babagan lemak visceral ora owah, nanging keamanané padha karo plasebo. Sawetara sinyal sekunder – kaya peningkatan massa lean lan rasa nyeri sing luwih sithik ing wanita sing nampa 10 mg, lan rasa kesejahteraan sing luwih apik ing dosis 5 mg – nuduhaké potensi manfaat. Nanging temuan iki asalé saka subkelompok lan laporan diri, rapamycin sing digunakake digawé khusus, lan durung ana bukti yèn iki nambah umur manungsa. Ing ngisor iki apa sing didhukung data lan apa sing ora.

This page is available in